Cardiovascular surgery devices and equipment are used in cardiac surgery and other cardiovascular procedures performed to repair structural defects of the cardiovascular system and damaged or blocked valves and vessels. The main product types in the cardiovascular surgery devices and equipment are beating heart surgery systems, cardiopulmonary bypass equipment, cardiac ablation devices, and perfusion disposables. Cardiopulmonary bypass equipment is used in open-heart surgeries and is operated by perfectionists. The various applications are congenital heart defects, cardiac arrhythmia, coronary heart disease, congestive heart failure, and other applications. These are used in home and ambulatory care, hospitals, diagnostic laboratories, and research laboratories. The cardiovascular surgery devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular surgery devices and equipment market statistics, including cardiovascular surgery devices and equipment industry global market size, regional shares, competitors with a cardiovascular surgery devices and equipment market share, detailed cardiovascular surgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular surgery devices and equipment industry. This cardiovascular surgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular surgery devices and equipment market size will grow from $1.68 billion in 2022 to $1.75 billion in 2023 at a compound annual growth rate (CAGR) of 3.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular surgery devices and equipment market size is expected to grow to $1.91 billion in 2027 at a CAGR of 2.2%. The rising geriatric population along with the rising deaths related to cardiovascular disorders is driving the cardiovascular surgical devices market. According to American Heart Association (AHA), in the US, approximately 43.7 million aged above 60 suffered from cardiovascular disorders. It is also reported by AHA that death related to cardiac diseases amount to 17.3 million per year and is expected to rise to more than 23.6 million by 2030, worldwide. Due to these factors, a higher number of surgeries are being performed, thereby driving the market. The cardiovascular surgical devices market may be restrained due to stringent and longer approval processes by the regulatory authorities. According to a researcher from Harvard Business School, innovative first-mover products such as implantable defibrillators or transcatheter heart valves are delayed for approvals by FDA, thereby adding to the development cost to the manufacturer. For new cardiovascular devices (first-entrants), the innovator spends 7.2 months longer than the first follow-on innovator. For example, Edwards Lifesciences trans-catheter heart valve was approved in Europe 4 years before it was approved in the USA. The study also estimated the financial loss associated with the delay in getting the approval. The delay may cost firms an average of $6.7 million to the already existing $94 million average prices to introduce a new medical device to market, thereby hampering companies’ pursuit of innovations. Companies in the cardiovascular surgery devices and equipment market are investing in second-generation bioresorbable stents and as well rectifying the glitches which occurred in the earlier version of bioresorbable stents. This advancing segment is poised to garner $247 million by 2025. Due to the all-new device features such as thinner strut thicknesses, faster resorption times, and better radial force, these are expected to grow at a higher growth rate. A higher elective procedure volume due to the less-invasive nature of PCIs, when compared to coronary artery bypass grafting, is expected to drive bioresorbable stents adoption. For instance, Amaranth Medical has developed three medical devices with thinner strut thickness, the latest bearing a magnitude of 100 microns. The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) made public, its priority list for medical device guidance documents. This would allow the companies in promoting innovation and as well save them from the stringent consequences of non-approval of any product. Thus, a clearer and transparent approval method would drive the cardiovascular surgical devices market in the future. Major players in the cardiovascular surgery devices and equipment market are Abbott Laboratories, Boston Scientific Corporation, Cook Medical, C.R.Bard, Abiomed, St.Jude medical, Angiodynamics Inc., Transmedics, Terumo cardiovascular systems corporation, and Edwards Life Science Corporation. North America was the largest region in the global cardiovascular surgery devices and equipment market in 2022. Western Europe was the second-largest region in the global cardiovascular surgery devices and equipment market. The regions covered in the cardiovascular surgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The cardiovascular surgery devices and equipment market consist of sales of perfusion disposables, beating heart surgery systems, cardiopulmonary bypass equipment, and cardiac ablation devices that are used for cardiovascular surgeries. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular surgery devices and equipment market is segmented - 1) By Product Type: Beating heart surgery systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposables 2) By End User: Home and Ambulatory care, Hospitals, Diagnostic laboratories, Research laboratories 3) By Application: Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Other Applications

Cardiovascular monitoring and diagnostic devices and equipment are used for the diagnosis, monitoring, and treatment of cardiovascular diseases. The main product types of cardiovascular monitoring and diagnostic devices and equipment are cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and Holter monitoring systems. ECG monitoring equipment is an electronic device that is used to record the electrical activity of the heart. The various types involved are heart disease and coronary heart disease. The various end-users involved are hospitals/physician clinics (continuous glucose monitors), home/emergency, and research and development (clinical trials, universities, CRO). The cardiovascular monitoring and diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular monitoring and diagnostic devices and equipment market statistics, including cardiovascular monitoring and diagnostic devices and equipment industry global market size, regional shares, competitors with a cardiovascular monitoring and diagnostic devices and equipment market share, detailed cardiovascular monitoring and diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular monitoring and diagnostic devices and equipment industry. This cardiovascular monitoring and diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular monitoring and diagnostic devices and equipment market size will grow from $3.12 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular monitoring and diagnostic devices and equipment market size is expected to grow to $4.31 billion in 2027 at a CAGR of 6.4%. The cardiovascular monitoring and diagnostic devices and equipment market is being driven by an increasing number of people suffering from obesity and diabetes. Risk factors including high blood pressure and high cholesterol are associated with obesity and diabetes leads to cardiovascular diseases. For instance, as per a study conducted by the American Heart Association (AMA), by 2030, 22.2 million CVD is expected to grow. According to another study conducted by AMA in the U.S., 26 million people have been diagnosed with diabetes, and above 9 million further, have the condition but it hasn't yet been diagnosed. The cardiovascular monitoring and diagnostic devices and equipment market is being restrained by the FDA's regulatory control over these devices based on the risks associated with this equipment. Cardiovascular monitoring and diagnostic devices fall into the class II category as per the FDA, which includes devices with moderate to high risk associated with usage. The Class II devices are specially controlled with performance standards which provide the manufacturers with performance specifications, postmarket surveillance which monitors the safety of the device after being released in the market, and also other standards like patient registries and special labeling requirements. For instance, Angel medical systems’ implantable cardiac monitor was unanimously rejected by a panel of FDA experts due to unmet performance specifications. ICMs continuously monitor the electrocardiogram (ECG) of the patient to conduct a real-time examination of the heart rhythm, for up to 36 months. ICMs are mostly used in the analysis of transitory symptoms which have an arrhythmic origin, such as unexplained palpitations. For example, in July 2020, Medtronic received U.S. Food and Drug Administration (FDA) clearance and European CE label approval for its Linq II insertable cardiac monitor (ICM) by remote programming, allowing clinicians to optimize device settings without the requirement for patients to return to the hospital. The launch of new products is a key trend gaining popularity in the cardiovascular monitoring and diagnostic devices and equipment market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in August 2022, SmartCardia SA, a medical equipment manufacturer in Switzerland, launched 7L patch, its 7-lead cardiac monitoring patch in India. This patch monitor combines medical wearable technology with artificial intelligence (AI) to provide predictive and personalized patient insights through remote monitoring. The 7L patch is tracked by SmartCardia’s AI platform is interpreted by cardiologists and certified cardiac technicians and performs real-time detection of important arrhythmia events at cardiologist level accuracy. The US FDA has classified cardiovascular monitoring and diagnostic devices into the Class II category, as they have a moderate to high risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, postmarket surveillance, and labeling requirements associated with device usage. For instance, the labeling should consist of contraindications, adverse reactions, precautions, warnings, and other instructions before the device is released into the market. Major players in the cardiovascular monitoring and diagnostic devices and equipment market are Medtronic PLC., Boston Scientific Corporation, GE Healthcare, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, St. Jude MedicalInc., Nihon Kohden Corporation, FUKUDA DENSHI Co. Ltd., and Sorin Group. North America was the largest region in global cardiovascular monitoring and diagnostic devices and equipment market in 2022. Western Europe was the second-largest region incardiovascular monitoring and diagnostic devices and equipment market. The regions covered in global cardiovascular monitoring and diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular monitoring and diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiovascular monitoring and diagnostic devices and equipment market consist of sales of cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and holter monitoring systems that are used for diagnosis and treatment of cardio diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular monitoring and diagnostic devices and equipment market is segmented - 1) By Product Type: Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems, Holter Monitoring Systems 2) By End-Use: Hospitals/Physician Clinic (Continuous Glucose Monitors), Home/Emergency, Research and Development (Clinical Trials, Universities, CRO) 3) By Type: Heart Disease, Coronary Heart Disease

Cardiovascular medical lasers are used in the treatment of medical conditions related to the heart. These lasers are commonly used during transmyocardial laser revascularization. The cardiovascular medical lasers market covered in this report is segmented by type into excimer lasers and carbon dioxide laser. The carbon dioxide laser aids in the removal of thin layers of skin while causing minimal damage to surrounding structures.These are used in various applications such as laser vascular anastomosis, transmyocardial laser revascularization, and laser angioplasty for peripheral arterial diseases that are used by end users such as hospitals, specialty clinics, and ambulatory surgery centres. The cardiovascular medical lasers market research report is one of a series of new reports from The Business Research Company that provides cardiovascular medical lasers market statistics, including cardiovascular medical lasers industry global market size, regional shares, competitors with a cardiovascular medical lasers market share, detailed cardiovascular medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular medical lasers industry. The cardiovascular medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular medical lasers market grew from $0.15 billion in 2022 to $0.21 billion in 2023 at a compound annual growth rate (CAGR) of 46.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular medical lasers market is expected to grow from $0.9 billion in 2027 at a CAGR of 43.2%. The rising prevalence of cardiovascular diseases is expected to drive the cardiovascular medical laser market. The increased prevalence of cardiovascular diseases can be attributed to the increase in the use of smoking, physical inactivity, and an unhealthy diet. For instance, according to the Centers for Disease control and prevention (CDC), 697,000 people died from heart diseases in 2020. According to the British Heart Foundation, coronary heart disease is responsible for around 64,000 deaths in the UK each year, an average of 180 people each day, or one death around every eight minutes. One in seven men and one in 12 women in the UK die from coronary heart disease. Therefore, the increasing prevalence of cardiovascular diseases is expected to drive the growth of cardiovascular medical lasers. Alternative treatment methods for cardiovascular ailments are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the cardiovascular medical laser market. Treatments of heart diseases using medical procedures such as coronary angioplasty, stent implantation, thrombolytic therapy, coronary artery bypass graft surgery (CABG), artificial pacemaker surgery, defibrillation, and heart valve surgery are more commonly used for the treatment of heart disease compared to the treatments employing lasers. According iData Research, around 340,000 CABG procedures are performed per year in the United States. This trend is expected to continue during the forecast period and limit the demand for cardiovascular medical lasers. Cardiovascular medical laser manufacturers are constantly investing in technologies for faster diagnosis and efficient treatment of heart conditions. Areas of technological advances include new wavelengths, more rugged setups, lower-cost systems, and other advancements are being combined with minimally invasive techniques. FDA cleared Ra Medical’s vascular products including cardiovascular lasers that can be used to treat peripheral arteries and veins. The laser works at 308-nanometer wavelength, which breaks chemical bonds and decomposes the blockage into its part, thereby reducing the risk for the patient. In October 2021, Laser MD Medspa, a US-based medical spa services company, acquired Young Medical Spa for an undisclosed amount. The acquisition would expand the company’s footprint in the state of Pennsylvania by adding four locations. Young Medical is a US-based provider of a full suite of cosmetic and aesthetic treatments, including laser hair removal, botox treatment, and others. Major players in the cardiovascular medical lasers market are Boston Scientific Corp., Cardiovascular Systems, AngioDynamics, Royal Philips NV, and RA Medical Systems. North America was the largest region in the cardiovascular medical lasers market in 2022. Asia-Pacific was the second largest region in the global cardiovascular medical lasers market report. The regions covered in the global cardiovascular medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular medical lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cardiovascular medical lasers market consists of sales of instruments such as excimer lasers and carbon dioxide lasers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cardiovascular medical lasers market is segmented - 1) By Type: Excimer Laser, Carbon Dioxide Laser 2) By Application: Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, and Laser Angioplasty for Peripheral Arterial Diseases 3) By End Use: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Soft tissue repair is defined as the replacement of wounded or damaged tissues with healthy tissues. The soft tissue repair market manufacture soft tissue repair products. The main types of soft tissue repair products include fixation devices, tissue patch or mesh, laparoscopic instruments. Fixation devices provide alignment and stabilization to the torn connective tissue. These include devices like cortical buttons and corresponding suture kits which helps enable the tension and the ability to attach tendon or tendon graft directly to the bone inside a pre-drilled socket. Tissue patch or mesh is a specialty biomaterial used for soft tissue repairs by supporting damaged tissues during the healing process. The laparoscopic instruments include various dissectors, graspers, scissors, electrodes, needle holders, and shaft and connection configurations for handling soft tissues during surgeries. Soft tissue repair is used in hernia repair, dural repair, skin repair, vaginal sling procedures, orthopedic repair, dental repair, breast reconstruction repair. These products are used by hospitals, clinics, research and academic institutes, others. The soft tissue repair market research report is one of a series of new reports from The Business Research Company that provides soft tissue repair market statistics, including soft tissue repair industry global market size, regional shares, competitors with a soft tissue repair market share, detailed soft tissue repair market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue repair industry. This soft tissue repair market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global soft tissue repair market size grew from $10.52 billion in 2022 to $11.74 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The soft tissue repair market size is expected to grow to $14.74 billion in 2027 at a CAGR of 5.8%. The increasing cases of sport-related injuries boosted the growth of the soft tissue repair market in the historic period. Sports injuries are injuries that occur when participating in sports or exercising. In sports, soft tissue injuries are the most frequent. Tissues that attach, sustain, or surround other body structures and organs are referred to as soft tissue. For instance, according to the National Safety Council, an American non-profit organization promoting health and safety, in 2021, Exercise equipment accounted for about 409,000 injuries which was the most in any sports category. Bicycles and accessories was the second largest cause of injuries injuring 375,797 injuries in the US. Therefore, the increasing prevalence of sport-related injuries drove the growth of the soft tissue repair market. The stringent regulatory standards for products like tissue mesh restrained the market growth in the historic period. The FDA requires manufacturers of these products to address safety concerns, through a rigorous premarket approval (PMA) pathway to demonstrate safety and effectiveness. The strong clinical requirements for surgical mesh and strict compliance to reduce risks could delay product approvals and thus restrain the market for soft tissue repair in the forecast period. Companies in the soft tissue market are investing in technological developments for increasing market share and providing innovative products to customers. Major companies operating in the soft tissue repair sector are focused on developing a technologically advanced solution for soft tissues. For instance, in April 2020, In2Bones, a USA-based designer, manufacturer, and distributor of medical devices for the treatment of disorders and injuries launched ClearGuard LE Endoscopic Soft Tissue Release System in the USA, which is used by orthopedic and podiatric specialists to treat a variety of foot problems. The ClearGuard LE Endoscopic Soft Tissue Release System gives orthopedic and podiatric specialists an easy-to-use, repeatable, and cost-effective system for high-volume lower extremity soft tissue surgeries such as plantar fascia, gastrocnemius, tarsal tunnel, and Morton's neuroma. In December 2020, Integra Lifesciences, a USA-based medical device company acquired ACell for $300 million. The acquisition is expected to expand Integra Lifesciences regenerative capabilities and is complementary to the existing tissue technologies portfolio of the company. ACell is a USA-based company that develops and manufactures unique extracellular matrix products to repair and remodel damaged tissues through remodeling. Major players in the soft tissue repair market are Organogenesis Inc., Stryker Corporation, Johnson & Johnson, Arthrex Inc., CryoLife Inc., Integra Lifesciences Corporation, Wright Medical Technology, Smith & Nephew plc, C.R. Bard Inc., Athersys Inc., Medtronic PLC., Zimmer Biomet Holdings Inc., Lifenet Health Inc., Isto Biologics, Covidien plc, Becton Dickinson and Company, LifeCell Corporation, Baxter Healthcare Corporation, and Boston Scientific Corporation. North America was the largest region in the soft tissue repair market in 2022. Asia-Pacific region is predicted to record fastest growth over the forecast period. The regions covered in the soft tissue repair report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Soft Tissue Repair market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The soft tissue repair market includes revenues earned by entities by tissue engineering, regeneration and tissue adhesive. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global soft tissue repair market is segmented - 1) By Product: Fixation Devices, Tissue Patch or Mesh, Laparoscopic Instruments 2) By Application: Hernia Repair, Dural Repair, Skin Repair, Vaginal Sling Procedures, Orthopedic Repair, Dental Repair, Breast Reconstruction Repair 3) By End User: Hospitals, Clinics, Research and Academic Institutes, Other End Users

Tissue diagnostic refers to a medical procedure that uses instruments to remove and stain tissue that must be sent to a laboratory or pathology department for documentation of what was excised for patient care (for tissue diagnostics). This offers measurements and descriptions, including any abnormalities, and an interpretation (or diagnosis) of health or disease status, under applicable legislation. The main types of products in tissue diagnostic are consumables, antibodies, kits, reagents, probes, instrument, slide staining system, scanner and tissue processing system. The antibodies are used for the detection of infections, recognition of allergies, and the measurement of hormones and other biological markers in the blood in tissue diagnostics. The technologies used in tissue diagnostic are immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and workflow management and special staining to detect diseases such as breast cancer, gastric cancer, lymphoma, prostate cancer and non-small cell lung cancer (NSCLC). Tissue diagnostic is mostly used in hospitals, research laboratories, pharmaceutical companies, and contract research organizations. The tissue diagnostic market research report is one of a series of new reports from The Business Research Company that provides tissue diagnostic market statistics, including tissue diagnostic industry global market size, regional shares, competitors with a tissue diagnostic market share, detailed tissue diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the tissue diagnostic industry. This tissue diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tissue diagnostic market size grew from $4.59 billion in 2022 to $4.95 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tissue diagnostic market size is expected to grow to $6.74 billion in 2027 at a CAGR of 8.0%. The rising incidence of cancer will propel the growth of the tissue diagnostics market during the forecast period. Cancer begins when genetic changes interfere, and cells start to grow uncontrollably and destroy body tissue and form a mass called a tumor. A tumor can be cancerous or benign. Cancer can be caused due to various reasons such as genetic mutations, cancer-causing chemicals (carcinogens), smoking, obesity, radiation, hormones, and others. As the instances of occurring cancer increase, there will be a significant need for diagnostic procedures such as tissue diagnostics help in determining the disease state. For instance, according to the US voluntary health organization dedicated to eliminating cancer, the American Cancer Society, in the USA, there were expected to be 1.8 million new cancer cases identified and 606,520 cancer deaths in 2020, and the number was expected to increase to 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in 2021. Therefore, the rising incidence of cancer drives the tissue diagnostics market. Technological advancement is a key trend gaining popularity in the tissue diagnostics market. Technological advancements include the introduction of automated tissue diagnostic devices/machines that collect multiple sample types, test multiple samples simultaneously, automate lab operations, and make them accessible to everyone. Key players are focused on developing and offering these automated tissue diagnostic systems to gain a competitive edge in the market and increase revenue. For instance, in July 2020, Mylab Discovery Solutions, an Indian molecular diagnostics company introduced Compact XL - Lab in a Box, India’s first fully automated Sample-to-PCR-ready system for molecular diagnostics. The new system automates lab operations from sample handling to RT-PCR ready tube preparation and does these operations in one single compact benchtop system. The system can collect various types of samples such as tissue, plasma, swabs, and sputum. In February 2022, Labcorp, a US-based global life sciences company, acquired Personal Genome Diagnostics (PGDx) for $575 million. With the addition of PGDx and its technology, Labcorp will expand its next-generation sequencing-based genomic profiling capabilities and strengthens the existing liquid biopsy capabilities. Personal Genome Diagnostics (PGDx) is an a US-based company offering cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. Major players in the tissue diagnostic market are Roche, Danaher, Thermo Fisher Scientific, Abbott, Agilent Technologies, Hologic, Qiagen, Bio Rad, BD, Genemed Biotechnologies Inc., Siemens, Merck KGaA, Cell Signaling Technology Inc., and Cellpath Ltd. North America was the largest region in the tissue diagnostic market in 2022. The regions covered in the tissue diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tissue diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The tissue diagnostic market includes revenues earned by entities by consumables and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tissue diagnostic market is segmented - 1) By Product: Consumables, Antibodies, Kits, Reagents, Probes, Instruments, Slide Staining System, Scanner, Tissue Processing system 2) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology And Workflow Management, Special Staining 3) By Disease: Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC) 4) By End User: Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations

The facial tissues refers to tissue papers or wipes or paper handkerchiefs that are thin, soft, absorbent, smooth, and disposable which are used for cleaning the face and reducing the spread of an infection or diseases as like swine flu. They serve as disposable alternatives to handkerchiefs made of cloth. The main types of facial tissues are box facial tissue and pocket facial tissues. Pocket facial tissues are soft, absorbent, disposable papers used for the cleansing of the face available in small packs. It is distributed by supermarkets and hypermarkets, departmental stores, convenience stores, online channels, and others that are used for home and away from home applications. The facial tissues market research report is one of a series of new reports from The Business Research Company that provides facial tissues market statistics, including facial tissues industry global market size, regional shares, competitors with a facial tissues market share, detailed facial tissues market segments, market trends and opportunities, and any further data you may need to thrive in the facial tissues industry. This facial tissues market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global facial tissues market size will grow from $9.99 billion in 2022 to $10.58 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global facial tissues market size is expected to grow to $12.98 billion in 2027 at a CAGR of 5.2%. The rise in the number of bacterial and viral infectious diseases has led to the rise in demand of sterilized, antibacterial and anti-viral facial tissues. The facial tissues are sterilized during the manufacturing process to prevent the spread of harmful microbes. The special anti-bacterial and antiviral facial tissues are infused with antibacterial and antiviral agents respectively to deactivate the bacteria in cold, flu viruses in cough, sneeze, or nasal discharge to prevent spreading of viruses to others. For instance, Kleenex anti-viral facial tissue manufactured by Kimberly-Clark has three soft layers, including a moisture-activated middle layer that kills 99.9% of cold and flu viruses in the tissue within 15 minutes. Thus, the rise in the number of infectious diseases and increased hygiene awareness among consumers is anticipated to drive the facial tissue market growth by enhancing the utilization of tissue products in the forecast period. The harmful effects caused by the use of chemically manufactured facial tissues can restraint the facial tissue market. The facial tissues are manufactured using different chemical substances. The use of poor- or low-quality chemical ingredients may cause harm to the skin of the consumers. The facial tissues treated with lotions, aromatic agents, antimicrobial agents, dyes and more have appeared in the market during recent years, and thus consumers both children and adults are at a higher risk being exposed to these substances through direct contact, especially with the skin and the mucous membranes, and via inhalation. For instance, facial tissues are often impregnated or infused with aromatic agents such as eucalyptus oils and menthol to alter the aroma and make the nose-blowing experience more pleasant. Hence, the lack of use of good quality of chemical ingredients is anticipated to halt the facial tissues market growth. Companies in the facial tissue market are increasingly using TAD (Through Air Drying) technology to manufacture facial tissues to have cost benefits. The TAD process used in tissue manufacturing was developed by P&G, Kimberly-Clark, and Scott, the machines are being utilized by some manufacturers such as Procter & Gamble for facial tissue production. In TAD process, the fibre web is dewatered and dried by non-compressive means, thereby avoiding the compaction that occurs during wet-pressing of the web in the conventional process. The use of these non-compressive water-removal technologies results in a product with improved properties such as high bulk, softness, cross direction (CD) stretches and absorbency. Fibre savings are possible for TAD tissue as the weight of the sheet can be reduced due to the higher bulk. Since fibre is usually the highest cost element in a tissue product, reduced fibre cost is the major advantage associated with the use of TAD technology. Leading players in the facial tissue paper market are now focusing on improving their production processes by adopting product extension techniques, novel marketing strategies and also making strong investments in R&D into already established factories by adding innovation to these facilities and boosting sales. In February 2020, Cartiere Carrrara, an Italy-based manufacturer of tissue paper products, acquired Carind S.r.l. (Carind) and CRC S.r.l. (CRC) for an undisclosed amount. This acquisition would make it possible for Cartiere Carrara to further solidify its place in the tissue paper sector, which has significant growth potential both in Italy and internationally. Carind S.r.l. (Carind) and CRC S.r.l. (CRC), are European leading manufacturers and distributors of tissue paper products. Major players in the facial tissues market are Kimberly-Clark, Procter and Gamble, APP, Hengan, Vinda, C&S PAPER, Metsa Tissue, WEPA, Cascades, and KP Tissue. Asia-Pacific was the largest region in the facial tissues market in 2022. North America was the second largest region in the global facial tissues market. The regions covered in the global facial tissues market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the facial tissues market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The facial tissues market consists of sales of mineral oil, ceresin, stearyl alcohol, and isopropyl palmitate. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global facial tissues market is segmented - 1) By Type: Box Facial Tissue, Pocket Facial Tissues 2) By Applications: At Home, Away From Home 3) By Distribution Channel: Supermarkets And Hypermarkets, Departmental Stores, Convenience Stores, Online Channels, Other Distribution Channels

Cardiovascular devices are used to monitor and control the irregular heartbeats and heart rhythm disorders. The main types in the cardiovascular devices market are cardiovascular surgery devices and equipment, cardiac rhythm management (CRM) devices and equipment, interventional cardiology devices and equipment, defibrillator devices and equipment, peripheral vascular devices and equipment, prosthetic heart valve devices and equipment, electrophysiology devices and equipment, and cardiac assist devices and equipment. Defibrillators are devices that restore the normal heartbeat by sending an electric pulse or shock to the heart. They are used to prevent or correct an arrhythmia, a heartbeat that is uneven or slow or fast. The type of expenditure is public, or private. The products used are instruments/equipment, and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The cardiovascular devices market research report is one of a series of new reports from The Business Research Company that provides cardiovascular devices market statistics, including cardiovascular devices industry global market size, regional shares, competitors with a cardiovascular devices market share, detailed cardiovascular devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular devices industry. This cardiovascular devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cardiovascular devices market grew from $59.55 billion in 2022 to $64.39 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular devices market is expected to grow to $83.35 billion in 2027 at a CAGR of 6.7%. Leadless pacemakers are being used for certain medical conditions such as slow heart rate (bradycardia), as they provide a less-invasive alternative to conventional pacemakers. A leadless pacemaker is a self-contained device that is inserted in the right ventricle of the heart without incisional access, leads, or a surgical pocket. Furthermore, the medical procedure for a leadless pacemaker can be performed in under 30 minutes, with few postprocedural restrictions. These devices are gaining popularity as they eliminate complications related to lead placement which includes cardiac perforation, pneumothorax, and lead dislodgement. Major companies manufacturing leadless pacemakers are Medtronic and Abbott. Major companies in the cardiovascular devices market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc., and Becton Dickinson. North America was the largest region in the global cardiovascular devices market in 2022. Western Europe was the second largest region in the global cardiovascular devices market. Africa. was the smallest region in the global cardiovascular devices market. The regions covered in the cardiovascular devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The cardiovascular devices market consists of sales of biventricular devices, and implantable cardiac loop recorders that are used for monitoring and treatment of cardiovascular disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular devices market is segmented - 1) By Type: Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs